Yale Study Identifies New Genetic Strategy to Boost Protein in Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease (ADPKD) is recognized as the leading inherited cause of kidney failure. Despite extensive research over the years, effective treatment options remain scarce, often resulting in patients needing dialysis or kidney transplants. Recently, a team of researchers at Yale University has proposed a promising new strategy for addressing this condition. Their findings, published in the Journal of Clinical Investigation, reveal a novel approach to increase the production of polycystin-1, a protein that is typically deficient in most cases of ADPKD.
ADPKD is characterized by the formation of fluid-filled cysts that progressively replace healthy kidney tissue, leading to a gradual decline in kidney function. Whitney Besse, MD, an assistant professor of medicine (nephrology) at Yale School of Medicine and the senior author of the study, explains that the disease is primarily caused by genetic mutations that diminish the amount of functional polycystin-1 available in the kidneys. Previous studies have indicated that even slight increases in polycystin-1 levels could yield therapeutic benefits and reduce cyst formation, making the enhancement of its production a long-standing goal for researchers in the field.
The innovative strategy explored in this study was inspired by a seminar Besse attended as part of the Yale Rare Disease Seminar Series. During this seminar, a Yale graduate student introduced her to upstream open reading frames (uORFs), which are short sequences of genetic code located before the main protein-coding region of a gene. Besse noted, "Prior to that talk, I'd never heard of uORFs. I learned that when a gene has active upstream open reading frames, the cell may be less efficient at producing the protein that gene is meant to produce. This caught my attention because polycystin-1 protein levels have always seemed lower than expected."
This presentation led Besse to hypothesize that uORFs might be limiting polycystin-1 production in patients with ADPKD. She theorized that by blocking these sequences, it might be possible to enhance the cells' ability to produce more of the protein, potentially offering a new treatment avenue for the disease. Supporting this hypothesis, publicly available data suggested that the gene responsible for polycystin-1 likely contains active uORFs.
To investigate this idea, Besse and her team developed in vitro models and created genetically engineered mouse models to study the effects of uORFs on polycystin-1 production. Their research demonstrated that disrupting the uORFs led to an increase in polycystin-1 levels by approximately two to four times, both in vitro and in vivo. Notably, this increase was effective in preventing the development of kidney cysts in mice predisposed to polycystic kidney disease.
Zhigui Li, PhD, an associate research scientist in Besse’s lab and the first author of the study, stated, "These models allowed us to show that small upstream open reading frames act as a translational brake on polycystin-1 production, and that releasing this brake can meaningfully change disease outcomes in vivo."
The findings from this research suggest a shift in the approach to genetic therapies. Besse remarked, "Many genetic therapies knock down or knock out a gene to decrease protein production, but for genes with active uORFs, blocking them is an approach that can increase the expression of a gene." This distinction is particularly significant for ADPKD, where even modest increases in polycystin-1 may offer therapeutic benefits.
Looking ahead, the research team aims to identify which patients might benefit most from this new approach, including whether specific genetic mutations could make certain individuals better candidates for treatment. They are also working to optimize therapies that can effectively block uORFs and reach the kidneys.
Li added, "We find that RNA-like genetic therapies called antisense oligonucleotides (ASOs) can block uORFs to increase polycystin-1 expression in cells, so we are now working on testing these and similar approaches in mice."
The research has garnered support from Yale Ventures, which has assisted Besse and her team in patenting this innovative approach as they strive to translate their findings into potential therapies for patients.
Besse expressed hope that this research will lead to new treatment options for individuals and families affected by ADPKD. "There are many patients and families who I have cared for in clinical settings and/or enrolled into our genetic research studies that motivate me. This is a disease that can have such a profound effect on families, and I look forward to the day when we can offer more," she said.
The research was supported by the National Institutes of Health through various awards and Yale University, with additional backing from the Doris Duke Charitable Foundation and the Polycystic Kidney Disease Foundation.




